220 related articles for article (PubMed ID: 17046265)
1. Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.
Kim IH; Nishi K; Tsai HJ; Bradford T; Koda Y; Watanabe T; Morisseau C; Blanchfield J; Toth I; Hammock BD
Bioorg Med Chem; 2007 Jan; 15(1):312-23. PubMed ID: 17046265
[TBL] [Abstract][Full Text] [Related]
2. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
[TBL] [Abstract][Full Text] [Related]
3. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension.
Jung O; Brandes RP; Kim IH; Schweda F; Schmidt R; Hammock BD; Busse R; Fleming I
Hypertension; 2005 Apr; 45(4):759-65. PubMed ID: 15699457
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway.
Liang Y; Jing Z; Deng H; Li Z; Zhuang Z; Wang S; Wang Y
Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):70-5. PubMed ID: 25986738
[TBL] [Abstract][Full Text] [Related]
6. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
[TBL] [Abstract][Full Text] [Related]
8. Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex.
Wu HF; Yen HJ; Huang CC; Lee YC; Wu SZ; Lee TS; Lin HC
J Biomed Sci; 2015 Oct; 22():94. PubMed ID: 26494028
[TBL] [Abstract][Full Text] [Related]
9. Adamantyl thioureas as soluble epoxide hydrolase inhibitors.
Burmistrov V; Morisseau C; Pitushkin D; Karlov D; Fayzullin RR; Butov GM; Hammock BD
Bioorg Med Chem Lett; 2018 Jul; 28(13):2302-2313. PubMed ID: 29803731
[TBL] [Abstract][Full Text] [Related]
10. Novel amide derivatives of 3-phenylglutaric acid as potent soluble epoxide hydrolase inhibitors.
Rezaee E; Amrolah SM; Nazari M; Tabatabai SA
Mol Divers; 2021 Feb; 25(1):45-53. PubMed ID: 31873869
[TBL] [Abstract][Full Text] [Related]
11. Soluble Epoxide Hydrolase Inhibition Attenuates Excitotoxicity Involving 14,15-Epoxyeicosatrienoic Acid-Mediated Astrocytic Survival and Plasticity to Preserve Glutamate Homeostasis.
Kuo YM; Hsu PC; Hung CC; Hu YY; Huang YJ; Gan YL; Lin CH; Shie FS; Chang WK; Kao LS; Tsou MY; Lee YH
Mol Neurobiol; 2019 Dec; 56(12):8451-8474. PubMed ID: 31257558
[TBL] [Abstract][Full Text] [Related]
12. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats.
Dorrance AM; Rupp N; Pollock DM; Newman JW; Hammock BD; Imig JD
J Cardiovasc Pharmacol; 2005 Dec; 46(6):842-8. PubMed ID: 16306811
[TBL] [Abstract][Full Text] [Related]
13. Linoleic Acid Metabolite DiHOME Decreases Post-ischemic Cardiac Recovery in Murine Hearts.
Bannehr M; Löhr L; Gelep J; Haverkamp W; Schunck WH; Gollasch M; Wutzler A
Cardiovasc Toxicol; 2019 Aug; 19(4):365-371. PubMed ID: 30725262
[TBL] [Abstract][Full Text] [Related]
14. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.
Koeners MP; Wesseling S; Ulu A; Sepúlveda RL; Morisseau C; Braam B; Hammock BD; Joles JA
Am J Physiol Endocrinol Metab; 2011 Apr; 300(4):E691-8. PubMed ID: 21266668
[TBL] [Abstract][Full Text] [Related]
15. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.
Imig JD; Zhao X; Zaharis CZ; Olearczyk JJ; Pollock DM; Newman JW; Kim IH; Watanabe T; Hammock BD
Hypertension; 2005 Oct; 46(4):975-81. PubMed ID: 16157792
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase: a novel therapeutic target in stroke.
Zhang W; Koerner IP; Noppens R; Grafe M; Tsai HJ; Morisseau C; Luria A; Hammock BD; Falck JR; Alkayed NJ
J Cereb Blood Flow Metab; 2007 Dec; 27(12):1931-40. PubMed ID: 17440491
[TBL] [Abstract][Full Text] [Related]
17. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility.
Kim IH; Morisseau C; Watanabe T; Hammock BD
J Med Chem; 2004 Apr; 47(8):2110-22. PubMed ID: 15056008
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.
Simpkins AN; Rudic RD; Schreihofer DA; Roy S; Manhiani M; Tsai HJ; Hammock BD; Imig JD
Am J Pathol; 2009 Jun; 174(6):2086-95. PubMed ID: 19435785
[TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase: a new target for cardioprotection.
Gross GJ; Nithipatikom K
Curr Opin Investig Drugs; 2009 Mar; 10(3):253-8. PubMed ID: 19333883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
